OPEN Foundation

Esketamine is approved in Europe for treating resistant major depressive disorder

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Mahase, E. (2019). Esketamine is approved in Europe for treating resistant major depressive disorder.,  10.1136/bmj.l7069
Link to full text

OPEN Foundation

INTERESTED IN PSYCHEDELIC RESEARCH AND THERAPIES?

Subscribe to the OPEN Foundation’s newsletter to stay in the loop, hear about our events, and become a part of a community dedicated to advancing psychedelics.

By clicking subscribe, I confirm to receive emails from the OPEN Foundation and agree with its privacy policy.